JP2011148799A5 - - Google Patents

Download PDF

Info

Publication number
JP2011148799A5
JP2011148799A5 JP2011027903A JP2011027903A JP2011148799A5 JP 2011148799 A5 JP2011148799 A5 JP 2011148799A5 JP 2011027903 A JP2011027903 A JP 2011027903A JP 2011027903 A JP2011027903 A JP 2011027903A JP 2011148799 A5 JP2011148799 A5 JP 2011148799A5
Authority
JP
Japan
Prior art keywords
cyanoindol
mania
fibromyalgia
anorexia
benzofuran
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011027903A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011148799A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2011148799A publication Critical patent/JP2011148799A/ja
Publication of JP2011148799A5 publication Critical patent/JP2011148799A5/ja
Pending legal-status Critical Current

Links

JP2011027903A 1999-05-27 2011-02-10 1−[4−(5−シアノインドール−3−イル)ブチル]−4−(2−カルバモイル−ベンゾフラン−5−イル)−ピペラジンおよびこの生理学的に受け入れられる塩の新規な使用 Pending JP2011148799A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99109295.8 1999-05-27
EP99109295 1999-05-27

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2000620944A Division JP4884588B2 (ja) 1999-05-27 2000-05-16 1−[4−(5−シアノインドール−3−イル)ブチル]−4−(2−カルバモイル−ベンゾフラン−5−イル)−ピペラジンおよびこの生理学的に受け入れられる塩の新規な使用

Publications (2)

Publication Number Publication Date
JP2011148799A JP2011148799A (ja) 2011-08-04
JP2011148799A5 true JP2011148799A5 (cg-RX-API-DMAC7.html) 2012-05-24

Family

ID=8238153

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000620944A Expired - Fee Related JP4884588B2 (ja) 1999-05-27 2000-05-16 1−[4−(5−シアノインドール−3−イル)ブチル]−4−(2−カルバモイル−ベンゾフラン−5−イル)−ピペラジンおよびこの生理学的に受け入れられる塩の新規な使用
JP2011027903A Pending JP2011148799A (ja) 1999-05-27 2011-02-10 1−[4−(5−シアノインドール−3−イル)ブチル]−4−(2−カルバモイル−ベンゾフラン−5−イル)−ピペラジンおよびこの生理学的に受け入れられる塩の新規な使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2000620944A Expired - Fee Related JP4884588B2 (ja) 1999-05-27 2000-05-16 1−[4−(5−シアノインドール−3−イル)ブチル]−4−(2−カルバモイル−ベンゾフラン−5−イル)−ピペラジンおよびこの生理学的に受け入れられる塩の新規な使用

Country Status (31)

Country Link
US (4) US6900212B1 (cg-RX-API-DMAC7.html)
EP (3) EP1410800B1 (cg-RX-API-DMAC7.html)
JP (2) JP4884588B2 (cg-RX-API-DMAC7.html)
KR (1) KR100683367B1 (cg-RX-API-DMAC7.html)
CN (3) CN101869565A (cg-RX-API-DMAC7.html)
AR (1) AR024112A1 (cg-RX-API-DMAC7.html)
AT (3) ATE438399T1 (cg-RX-API-DMAC7.html)
AU (1) AU771778B2 (cg-RX-API-DMAC7.html)
BR (1) BR0010948A (cg-RX-API-DMAC7.html)
CA (3) CA2372668C (cg-RX-API-DMAC7.html)
CY (2) CY1105750T1 (cg-RX-API-DMAC7.html)
CZ (1) CZ295623B6 (cg-RX-API-DMAC7.html)
DE (3) DE60042710D1 (cg-RX-API-DMAC7.html)
DK (3) DK1410800T3 (cg-RX-API-DMAC7.html)
ES (3) ES2219342T3 (cg-RX-API-DMAC7.html)
HK (1) HK1048444B (cg-RX-API-DMAC7.html)
HU (1) HU229059B1 (cg-RX-API-DMAC7.html)
IL (2) IL146707A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA01012172A (cg-RX-API-DMAC7.html)
MY (1) MY135627A (cg-RX-API-DMAC7.html)
NO (2) NO322120B1 (cg-RX-API-DMAC7.html)
PL (3) PL199650B1 (cg-RX-API-DMAC7.html)
PT (3) PT1736158E (cg-RX-API-DMAC7.html)
RU (1) RU2237477C2 (cg-RX-API-DMAC7.html)
SI (2) SI1185272T1 (cg-RX-API-DMAC7.html)
SK (1) SK287851B6 (cg-RX-API-DMAC7.html)
TR (1) TR200103361T2 (cg-RX-API-DMAC7.html)
TW (1) TW518218B (cg-RX-API-DMAC7.html)
UA (1) UA74337C2 (cg-RX-API-DMAC7.html)
WO (1) WO2000072832A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200110485B (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW518218B (en) * 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
UA76130C2 (en) 2000-11-20 2006-07-17 Merck Patent Gmbh Use of compounds combining properties of selective inhibitors of serotonin re-uptake and agonists of 5-ht1a receptor for treatment of irritable bowel syndrome
DE10112151A1 (de) * 2001-03-14 2002-09-19 Merck Patent Gmbh Substituierte Benzofuran-2-carbonsäureamide
UA76758C2 (uk) 2001-06-19 2006-09-15 Мерк Патент Гмбх Поліморфні форми гідрохлориду 1-'4-(5-ціаноіндол-3-іл)бутил-4-(2-карбамоїлбензофуран-5-іл)піперазину
DE10217006A1 (de) * 2002-04-16 2003-11-06 Merck Patent Gmbh Substituierte Indole
DE10305739A1 (de) * 2003-02-11 2004-08-19 Merck Patent Gmbh Benzofuranderivate
WO2004082686A2 (en) * 2003-03-13 2004-09-30 Dynogen Pharmaceuticals, Inc. Use of compounds with combined 5-ht1a and ssri activities to treat sexual dysfunction
US7893261B2 (en) 2004-03-26 2011-02-22 Baylor University Serotonin reuptake inhibitors
NZ572585A (en) 2006-05-30 2011-02-25 Astrazeneca Ab 1,3,4-Oxadiazole derivatives as DGAT1 inhibitors
EP2234978B1 (en) 2007-12-20 2015-02-25 AstraZeneca AB Carbamoyl compounds as dgat1 inhibitors 190
AU2010261499A1 (en) 2009-06-19 2012-01-12 Astrazeneca Ab Pyrazine carboxamides as inhibitors of DGAT1
AU2010316172B2 (en) 2009-11-06 2015-11-12 Sk Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome
EP2496228B1 (en) 2009-11-06 2014-01-15 SK Biopharmaceuticals Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
TWI577377B (zh) * 2010-09-16 2017-04-11 Viiv醫療保健公司 醫藥組合物
WO2012131706A1 (en) 2011-03-20 2012-10-04 Cadila Healthcare Limited Amorphous form of vilazodone hydrochloride and process for its preparation
CN102949364A (zh) * 2011-08-30 2013-03-06 天津药物研究院 一种含有效成分盐酸维拉佐酮的缓释片
EP2861586A4 (en) 2012-06-13 2015-11-11 Apotex Inc FORMS OF VILAZODONE AND METHODS OF PREPARATION THEREOF
CN102860993A (zh) * 2012-10-16 2013-01-09 北京诚创思达医药科技有限公司 一种盐酸维拉唑酮快速释放片剂及其制备方法
WO2014064715A2 (en) 2012-10-22 2014-05-01 Cadila Healthcare Limited Amorphous form of vilazodone hydrochloride and process for preparing thereof
CN102977083A (zh) * 2012-12-17 2013-03-20 南京海纳医药科技有限公司 1-[4-(5-氰基吲哚-3-基)丁基]-4-(2-氨甲酰-苯并呋喃-5-基)-哌嗪盐酸盐的新晶型xⅶ及其制备方法
RS59687B1 (sr) 2013-01-22 2020-01-31 Vistagen Therapeutics Inc Oblici doziranja i terapeutske primene l-4-hlorkinurenina
EP2824104A1 (en) 2013-07-12 2015-01-14 Sandoz AG Process for the preparation of form III of Vilazodone hydrochloride
PL3297619T3 (pl) * 2015-05-22 2023-02-13 Vistagen Therapeutics, Inc. Terapeutyczne zastosowania L-4-chlorokinureniny

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2672052B1 (fr) * 1991-01-28 1995-05-24 Esteve Labor Dr Derives d'aryl (ou heteroaryl)-piperazinyl-alkyl-azoles, leur preparation et leur application en tant que medicaments.
SE9201239D0 (sv) * 1992-04-21 1992-04-21 Kabi Pharmacia Ab Agents for treating substance abuse disorders
DE4333254A1 (de) * 1993-09-30 1995-04-06 Merck Patent Gmbh Piperidine und Piperazine
GB9406857D0 (en) * 1994-04-07 1994-06-01 Sandoz Ltd Improvements in or relating to organic compounds
DE19514567A1 (de) 1995-04-20 1996-10-24 Merck Patent Gmbh Benzofurane
US5763457A (en) * 1995-11-13 1998-06-09 Eli Lilly And Company Method for treating anxiety
US5914394A (en) * 1997-03-27 1999-06-22 Millenium Pharmaceuticals, Inc. Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders
US5900420A (en) * 1997-06-19 1999-05-04 Cole; William L. Method for treating chronic fatigue syndrome and fibromyalgia with buprenorphine
US6470933B1 (en) * 1998-03-09 2002-10-29 Pirelli Pneumatici S.P.A. Tire containing at least part of an electrical current generator intended for the supply of sensors and/or other electrical devices present within the tire, and method for manufacture the said tire
FR2781671A1 (fr) * 1998-07-28 2000-02-04 Synthelabo Compositions pharmaceutiques contenant un inhibiteur de la recapture de la serotonine et leur application en therapeutique
TW518218B (en) * 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
EP1612813A3 (en) * 2001-09-11 2009-12-09 JTEKT Corporation Magnetizing device with pole array, and magnetizing method
FR2844591B1 (fr) * 2002-09-13 2005-04-15 Arvinmeritor Light Vehicle Sys Dispositif de determination du deplacement d'un arbre

Similar Documents

Publication Publication Date Title
JP2011148799A5 (cg-RX-API-DMAC7.html)
IL260297A (en) Process for preparing n-[5-(5,3-difluoro-benzyl)-h1-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino )–benzamide
EA201401150A1 (ru) Аминоиндолилзамещенные имидазолпиримидины и их применение в качестве лекарственных средств
JP2013173782A5 (cg-RX-API-DMAC7.html)
HRP20241145T1 (hr) Biciklički aza spojevi kao agonisti muskarinskih receptora
JP2013519675A5 (cg-RX-API-DMAC7.html)
JP2012072162A5 (cg-RX-API-DMAC7.html)
JP2013519683A5 (cg-RX-API-DMAC7.html)
NO343929B3 (no) 1-[2-(2,4-dimetylfenylsulfanyl-fenyl]-piperazin som en forbindelse med kombinert serotoninreopptak, 5-HT3- og 5HT1A-aktivitet for behandlingen av kognitiv smerte
JP2015147774A5 (cg-RX-API-DMAC7.html)
JP2013530958A5 (cg-RX-API-DMAC7.html)
HRP20120558T1 (hr) Kapa-selektivni antagonist opioidnih receptora
PH12014502363A1 (en) N-aryltriazole compounds as lpar antagonists
HRP20180709T1 (hr) Farmaceutski dozni oblik kapsule koji obuhvaća suspenzijsku formulaciju derivata indolinona
JP2011524850A5 (cg-RX-API-DMAC7.html)
JP2016523260A5 (cg-RX-API-DMAC7.html)
PH12014502789A1 (en) N-alkyltriazole compounds as lpar antagonists
IL217052A0 (en) Nanostructured sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions of them, process for the preparation thereof and pharmaceutical compositions containing them
IL236925A0 (en) Processes for the preparation of (s)-3-4-((4-morpholinomethyl)benzyl)oxy)-1-oxoisoindoline-2-yl)piperidine-6,2-dione and acceptable pharmaceutical forms thereof
MX2011008336A (es) Derivados de dihidroquinolinona.
JP2017537912A5 (cg-RX-API-DMAC7.html)
IL230487B (en) 6-(n-(7-chloro-1-hydroxy-3,1-dihydrobenzo[c][1,2]oxaborole-5-yl)methylsulfonamido)-5-cyclopropyl-2-(4-fluorophenyl)-n- Methylbenzofuran-3-carboxamide, their salts and pharmaceutical preparations containing them
WO2015173701A3 (en) Pharmaceutical compositions comprising danirixin for treating infectious diseases
JP2013538206A5 (cg-RX-API-DMAC7.html)
MY167075A (en) Benzodioxole derivative and preparation method and use thereof